Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-03-31
2008-08-26
Crane, L. E. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S351000, C514S354000, C514S357000, C514S432000, C514S459000, C514S460000, C514S532000, C514S538000, C514S603000, C546S184000, C546S192000, C549S028000, C549S356000, C549S416000, C549S426000, C549S427000, C549S428000, C560S009000, C560S012000, C560S013000, C564S080000, C568S028000, C568S030000, C568S031000, C568S036000
Reexamination Certificate
active
07417059
ABSTRACT:
The present invention is directed to a class of cyclohexene derivatives bearing sulfamoyl and ester groups which have an inhibitory activity on nitric oxide (NO) production and cytokine production, and are useful as an agent for the prophylaxis and/or treatment of diseases such as, cardiac disease, autoimmune disease, inflammatory disease, central nervous system disease, infectious disease, sepsis, and septic shock.
REFERENCES:
patent: 5378703 (1995-01-01), Dean et al.
patent: 6495604 (2002-12-01), Ichimori et al.
patent: 7078540 (2006-07-01), Tamura et al.
patent: 2003/0100580 (2003-05-01), Dhanak et al.
patent: 2004/0002425 (2004-01-01), Saitou et al.
patent: 96/31492 (1996-10-01), None
patent: 99/46242 (1999-09-01), None
Försterman et al., “Nitric Oxide Synthase Isozymes—Characterization, Purification, Molecular Cloning, and Functions,” Hypertension, 23(No. 6, pt. 2), 1121-1131 (Jun. 1994).
Kröncke et al., “Inducible Nitric Oxide Synthase in Human Diseases,” Clinical and Expimental Immunology, 113, 147-156 (1998).
Yamada et al., “Discovery of Novel and Potent Small-Molecule Inhibitors of NO and Cytokine Production as Antisepsis Agents: Synthesis and Biological Activity and Alkyl 6-(N-Substituted sulfamyl)cyclohexy-1-ene-1-carboxylate,” J. Medicinal Chemistry, 48(23), 7457-7467 (2005); WEB publ Oct. 14, 2005.
Pugh et al. (eds.), Stedman's Medical Dictionary, 27th Edition, Lippincott Williams & Wilkins, Baltimore, MD, 2000, only p. 1021 supplied.
Ketteler et al., “Nitric Oxide in Sepsis-Syndrome: Potential Treatment of Septic Skock by Nitric Oxide Synthase Antagonists,” Kidney International, 53(Suppl. 64), S27-S30 (1998): copy supplied by applicant.
Satoh et al., “Induicble Nitric Oxide Synthase and Tumor Necrosis Factor-Alpha in Myocardium in Human Dilated Cardiomyopathy,” Journal of the American College of Cardiology, 29(4), 716-724 (Mar. 15, 1997): copy supplied by applicant.
Ishiyama et al., “Nitric Oxide Contributes to the Progression of Myocardial Damage in Experimental Autoiummune Myocarditis in Rats,” Circulation, 95(2), 489-496 (Jan. 21, 1997): copy supplied by applicant.
Kettelhut et al., “The Toxic Effects of Tumor Necrosis Factor in vivo and Their Prevention by Cyclooxygenase Inhibitors,” Proc. of the National Academy of Sciences USA, 84, 4273-4277 (Jun. 1987): copy supplied by applicant.
Weisensee et al., “Effects of Cytokines on the Contractility of Cultured Cardiac Myocytes,” International Journal of Immunopharmacology, 15(5), 581-5878 (1993): copy supplied by applicant.
Robaye et al., “Tumor Necrosis Factor Induces Apoptosis (Programmedc Cell Death) in Normal Endothelial Cells in Vitro,” American Journal of Pathology, 138(2), 447-453 (Feb. 1991): copy supplied by applicant.
Graafland, T., et al. “Structure and reactivity in intramolecular catalysis. Catalysis of sulfonamide hydrolysis by the neighboring carboxyl group”, J. Am. Chem. Soc., vol. 101, No. 23 (Nov. 7, 1979), pp. 6981-6991.
Teun Graafland, Wim C. Nieuwpoort and Jan B. F. N. Engberts, “Steric Effects in the Intramolecular Carboxyl-Catalyzed Hydrolysis of Sulfonamides. Ab Initio Quantum Chemical Studies of the Pentacoordinated Sulfur Intermediate” inJournal of the American Chemical Society, 1981, 103, pp. 4490-4494.
Katrin Illgen, Christine Hartung, Rainer Herzschuh and Bärbel Schulze, “3-Hydroperoxy-4,5,6,7-tetrahydro-toluene-2,a-sultims: Preparation and Reactions” inMolecules, presented Sep. 1-4, 1996, 1, pp. 139-141.
Bärbel Schulze, Sabine Kirrbach, Katrin Illgen and Peter Fuhrmann, “Synthesis of Stable Hydroperoxides of Sultams by Oxidation of Isothiazolium Salts” inTetrahedron, Jan. 15, 1996, vol. 52, No. 3, pp. 783-790.
Arend et al., “IL-1 Receptor Antagonist and IL-1β Production in Human Monocytes are Regulated Differently”, Journal of Immunology, vol. 147, No. 2, pp. 1530-1536, Sep. 1, 1991.
Dinarello et al., “Blocking IL-1: Interleukin 1 Receptor Antagonist in vivo and in vitro”, Immunology Today, vol. 12, No. 11, pp. 404-410, 1991.
Neuner et al., “Pentoxifylline in vivo Down-Regulates the Release of IL-1β, IL-6, IL-8 and Tumor Necrosis Factor-α by Human Peripheral Blood Mononuclear Cells”, Immunology, vol. 83, No. 2, pp. 262-267, Oct. 1994.
Matsuda et al., “Establishiment of an Interleukin 6 (IL6)/B Cell Stimulatory Factor 2-Dependent Cell Line and Preparation of Anti-IL6 Monoclonal Antibodies”, European Journal of Immunology, vol. 18, pp. 951-956, Jun. 1988.
Cohen et al., “CNI-1493 Inhibits Monocyte/Macrophage Tumor Necrosis Factor by Suppression of Translation Efficiency”, Proc. National Academy of Science USA, vol. 93, pp. 3967-3971, Apr. 1996.
Forstermann et al., “Nitric Oxide Synthase Isozymes—Characterization, Purification, Molecular Cloning, and Functions”, Hypertension, vol. 23, No. 6, Part 2, pp. 1121-1131, Jun. 1994.
Kroncke et al., “Inducible Nitric Oxide Synthase in Human Diseases”, Clinical and Experimental Immunology, vol. 113, pp. 147-156, 1998.
Ichikawa Takashi
Ii Masayuki
Tamura Norikazu
Crane L. E.
Takeda Pharmacetical Company Limited
Wenderoth , Lind & Ponack, L.L.P.
LandOfFree
Substituted aromatic-ring compounds, process for producing... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted aromatic-ring compounds, process for producing..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted aromatic-ring compounds, process for producing... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4013092